Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CTSD | P07339 | 1/20 | 0.67 |
| ▸ | CTSE | P14091 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789451 | 1.00 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5789446 | 1.00 | REN (1.00) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5729858 | 0.89 | REN (0.83) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5786350 | 0.89 | REN (0.83) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5786344 | 0.89 | REN (0.83) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5730812 | 0.89 | REN (0.83) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5925899 | 0.89 | REN (0.83) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5730815 | 0.89 | REN (0.83) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5730142 | 0.89 | REN (0.83) | RENCYP3A4CTSDCTSE | |
| SCHEMBL5729859 | 0.89 | REN (0.83) | RENCYP3A4CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258648-A1 | 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-11-16 | — | — | US | claimed |
| EP-1622685-A1 | 9-AZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096366-A1 | 9-AZABICYCLO’3.3.1!NON-6-EE DERIVATIVES WITH A HETEROATOM AT THE 3-POSITION AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-11 | — | — | WO | claimed |
| US-20060258648-A1 | 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258648-A1 | 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors | REN, ACE, AGTR1 | REN 1/4885CYP3A4 294/4885CTSD 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.